Teva announced the launch of Levalbuterol Inhalation Solution, the generic version of Xopenex Inhalation Solution Concentrate.

Xopenex is a beta2-adrenergic agonist indicated for the treatment or prevention of bronchospasm in patients ≥6 years of age with reversible obstructive airway disease. Activation of beta2-adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3′, 5′-adenosine monophosphate (cyclic AMP). Levalbuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Increased cyclic AMP concentrations are also associated with the inhibition of release of mediators from mast cells in the airway.

RELATED: Asthma Treatments: Inhalations

Levalbuterol Inhalation Solution is available as a 1.25mg/0.5mL strength vials in 30-count cartons.

For more information call (888) 838-2872 or visit